Transglutaminase 4 (TGM4) expression is primarily confined to the luminal epithelia of prostate tumors, and TGM4-pulsed monocyte-derived DCs (moDCs) expanded CD8+ and CD4+ T cells, thus making TGM4 a potential vaccine candidate to treat PCa.43 This evidence concerns the gene CD4 and prostate neoplasm.